Home / Clinical Decision Support & Reference / Vesta Bladder Risk Stratify Dx

Vesta Bladder Risk Stratify Dx

by Valar Labs · Based in United States → — Analyzing the tumor to predict cancer treatment response

Oncology Pathology Urology

Website Contact

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Regulatory Status Disclosed

Overview

Valar Labs’ Vesta Bladder Risk Stratify Dx is an innovative AI-enabled digital pathology prognostic test designed to revolutionize treatment decisions for bladder cancer patients. This advanced diagnostic tool leverages artificial intelligence to interpret complex features within the tumor microenvironment from routine stained pathology slides. By providing unparalleled insights, Vesta aims to remove the uncertainty often associated with selecting optimal cancer therapies.

The core functionality of Vesta Bladder Risk Stratify Dx involves generating precise risk assessments for bladder cancer patients. Crucially, it predicts individual patient responses to specific treatments, notably BCG (Bacillus Calmette-Guérin) therapy, which is a common immunotherapy for early-stage bladder cancer. This predictive capability empowers physicians to make more informed, evidence-based decisions, thereby improving the likelihood of successful treatment outcomes and enhancing patient confidence.

Vesta Bladder Risk Stratify Dx has received FDA Breakthrough Device Designation, underscoring its potential to offer a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. This designation facilitates an expedited review process, highlighting the significant clinical need and potential impact of this technology. Valar Labs is also actively engaged in partnerships with pharmaceutical companies, deploying their AI algorithms to accelerate early research, discover novel biomarkers, and streamline R&D programs for various cancers.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

AI-powered digital pathology analysis
Prognostic risk assessment for bladder cancer
Prediction of BCG treatment response
Interpretation of tumor microenvironment
Actionable reports for therapy selection
FDA Breakthrough Device Designation

Use Cases

Bladder cancer patient risk stratification
Guiding treatment decisions for BCG therapy
Identifying optimal therapy for bladder cancer patients
Advancing precision oncology research

What Physicians Need to Know

Evidence Base

Vesta Bladder Risk Stratify Dx leverages advanced Computational Histology AI (CHAI) to analyze pathology slides, providing clinical insights for non-muscle invasive bladder cancer (NMIBC). Its biomarker models have been developed and validated in over 1,000 NMIBC patients, with Valar Labs' board-certified pathologists creating over 500,000 annotations to train the AI platform. Published research, including in European Urology, demonstrates that Vesta's biomarkers accurately predict recurrence and disease progression, outperforming existing guideline-based risk stratification. The technology extracts predictive signals from pathology images that are not visible to the human eye.

Clinical Validation Studies

Clinical studies show that Vesta Risk Stratify biomarkers accurately predict recurrence and disease progression, surpassing current guideline-based risk stratification. In a multi-center real-world study, Vesta results led to a change in primary management for 67% of high-grade NMIBC cases, including shifts in treatment modality and intravesical agents. Patients with high progression scores demonstrated an almost 4x elevated risk of disease progression within 3 years, while those with high recurrence scores had a 2x elevated risk of high-grade recurrence over up to 24 months. The Vesta Bladder BCGPredict test, part of the Vesta portfolio, also predicts response to BCG therapy, identifying patients with a 2x elevated risk of non-response.

Clinical Workflow Integration

Vesta Bladder testing is designed for seamless integration into existing clinical workflows, utilizing standard hematoxylin and eosin (H&E) stained pathology slides from routine procedures, eliminating the need for additional biopsies or sample collection. Results are typically available within approximately 3 days of sample receipt at Valar Labs' CLIA-certified and CAP-accredited laboratory. Partnerships, such as with Lumea, aim to integrate Vesta tests into digital pathology platforms, providing urologists and pathologists with streamlined access to diagnostic information. The platform supports clinicians at key decision points across the cancer care continuum, from initial risk assessment to treatment selection.

Physician Tip

Vesta Bladder Risk Stratify Dx offers individualized risk assessments for recurrence and progression in non-muscle invasive bladder cancer (NMIBC), providing a more refined understanding of patient risk beyond traditional clinical factors. This AI-powered tool analyzes routine H&E pathology slides, delivering actionable insights without requiring additional biopsies. The FDA Breakthrough Device Designation highlights its potential to address unmet needs in bladder cancer prognosis. Consider utilizing Vesta to guide decisions on surveillance, monitoring, and surgical management, particularly for patients in the 'gray zone' of current guideline-based risk stratification. Additionally, the companion Vesta Bladder BCGPredict test can help predict response to BCG therapy, which is invaluable for optimizing treatment selection and managing potential BCG shortages.

Vesta Bladder tests are engineered for seamless integration into existing clinical workflows, leveraging standard pathology slides already collected during routine care. Valar Labs actively collaborates with digital pathology platforms, such as Lumea, to ensure direct and efficient access to Vesta test results for urologists and pathologists. All tests are processed in Valar Labs' CLIA-certified and CAP-accredited laboratory, upholding stringent quality standards. The underlying AI platform also powers other lab-developed tests for prostate and pancreatic cancer, indicating a robust and extensible integration capability for a broader range of oncology diagnostics.

At a glance

Deployment On Premise

Visit site

Details

Category	Clinical Decision Support & Reference, Oncology AI, Pathology AI
Pricing	Unknown Valar Labs engages in subscription models for ongoing access to its diagnostic technologies The transaction structure is primarily B2B, providing diagnostic tools and services directly to healthcare institutions and pharmaceutical partners
Deployment	On-premise
Languages	English
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	1 AI-estimated Vesta Bladder Risk Stratify Dx received FDA Breakthrough Device Designation, becoming the first AI-powered digital pathology prognostic test in bladder cancer to receive this status. This designation expedites the development and review of the device, potentially leading to faster FDA clearance and patient access. Valar Labs also offers a portfolio of AI-powered lab developed tests (LDTs) for bladder, prostate, and pancreatic cancer, which are orderable through their CLIA-certified and CAP-accredited laboratory.
Integrations
EHR	Not specified
Specialties	Oncology, Pathology, Urology

Social Proof

Customers	unknown
Notable	unknown

What the Web Says

Vesta Bladder Risk Stratify Dx by Valar Labs is an AI-powered diagnostic tool for non-muscle invasive bladder cancer (NMIBC) that analyzes routine pathology slides to provide individualized risks of disease recurrence and progression. It also includes Vesta Bladder BCGPredict, which forecasts a patient's response to BCG treatment, a standard therapy for NMIBC. The technology aims to offer more precise insights than traditional methods, helping physicians tailor treatment plans and optimize patient outcomes.

Overall: Mixed

Strengths

Provides individualized risk assessments for recurrence and progression.
Predicts response to BCG treatment, which is crucial given BCG shortages.
Utilizes AI to extract predictive signals from pathology images not visible to the human eye.
Seamless integration into existing clinical workflows.
Received FDA Breakthrough Device Designation, highlighting its potential to address unmet medical needs.
Shown to influence clinical decision-making in a significant number of cases in real-world studies.

Limitations

Limited information available from independent tech reviewers, G2, or Capterra specifically for the medical diagnostic product.
Relatively new technology, so long-term outcomes and widespread adoption data are still emerging.
Cost and insurance coverage may be a concern for some patients, although Valar Labs offers a Financial Access Program.
Requires pathology slides, which may involve a biopsy procedure if not already available.
While studies show impact on decision-making, the ultimate impact on patient survival rates needs further long-term evaluation.
No specific negative physician reviews were found in the search results.

Last updated: 2026-08-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Vesta Bladder Risk Stratify Dx

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

OEM News

FDA Breakthrough Device Designation Granted for Vesta Bladder Risk Stratify Dx

Valar Labs' Vesta Bladder Risk Stratify Dx, an AI-powered digital pathology prognostic test for bladder cancer, has received FDA Breakthrough Device Designation. This marks the first AI-powered digital pathology prognostic test in bladder cancer to achieve this status.

2026-08

Urology Times

FDA grants breakthrough device designation to Vesta Bladder Risk Stratify Dx

The FDA has granted Breakthrough Device Designation to Vesta Bladder Risk Stratify Dx, an AI-enabled digital pathology assay for bladder cancer prognostication. This designation aims to expedite the development and review of devices that offer more effective diagnosis or treatment for life-threatening conditions.

2026-05

Medical Device Network

Valar Labs hits US first with breakthrough designation for AI bladder cancer test

Valar Labs' Vesta Bladder Risk Stratify Dx has become the first AI-based digital pathology prognostic test in bladder cancer to receive FDA Breakthrough Device Designation. The test analyzes stained pathology slides to generate risk assessments, aiding in treatment decisions.

2026-05

Pharmaceutical Outsourcing

Valar Labs Gets FDA Breakthrough Device Nod for Vesta Bladder Cancer Risk Test

Valar Labs announced that the FDA granted Breakthrough Device Designation to Vesta Bladder Risk Stratify Dx, making it the first AI-powered digital pathology prognostic test in bladder cancer to receive this designation. This status may expedite FDA clearance and patient access.

2026-05

360Dx

Valar Labs Bladder Cancer Prognostic Nabs FDA Breakthrough Device Designation | 360Dx

Valar Labs' Vesta Bladder Risk Stratify Dx, an AI-based digital pathology assay for bladder cancer, has received breakthrough device designation from the FDA. This test uses routine H&E stained slides and computational pathology to help clinicians tailor treatments.

2026-05

Clinical Lab Products

FDA Grants Breakthrough Designation to AI Bladder Cancer Prognostic Test

The FDA has granted Breakthrough Device Designation to Valar Labs' Vesta Bladder Risk Stratify Dx, an AI-powered digital pathology prognostic test for bladder cancer. The test analyzes routine pathology slides to assess patient risk and aid in treatment planning.

2026-05

Business Wire

Valar Labs Receives FDA Breakthrough Device Designation for Vesta Bladder Risk Stratify Dx - Business Wire

Valar Labs announced that its Vesta Bladder Risk Stratify Dx has received FDA Breakthrough Device Designation, recognizing its potential to address an unmet need in bladder cancer prognosis. The test uses AI foundation models to analyze pathology slides and generate risk assessments.

2026-05

Business Wire

Valar Labs' CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer - Business Wire

Valar Labs published research in European Urology validating its Vesta platform for prognosticating outcomes in high-grade Ta non-muscle invasive bladder cancer. The study shows Vesta Risk Stratify biomarkers accurately predict recurrence and progression, outperforming existing risk stratification methods.

2025-06

Videos

Product demos, reviews, and walkthroughs for Vesta Bladder Risk Stratify Dx.

This Entrepreneur Is Helping Cancer Patients Find Accurate Treatment By Analyzing Images With AI

How AI Will Create 'An Abundance' Of Healthcare Tech Advancement

How Fear Can Stunt Business Growth For All Entrepreneurs

View all on YouTube

Frequently Asked Questions

How does Vesta Bladder Risk Stratify Dx work and what specific clinical insights does it provide?

Vesta Bladder Risk Stratify Dx is an AI-powered digital pathology prognostic test that analyzes routine hematoxylin and eosin (H&E) stained pathology slides. It extracts predictive signals from the tumor microenvironment to provide individualized risk assessments for bladder cancer recurrence and progression, and predicts patient response to treatments like BCG therapy.

How can Vesta Bladder Risk Stratify Dx improve my clinical decision-making for bladder cancer patients?

This test offers more precise prognostic tools than traditional methods, helping to resolve uncertainty in treatment planning for non-muscle-invasive bladder cancer. It enables physicians to match treatment intensity to a patient's true biological risk, guiding decisions on therapy selection, escalation, de-escalation, and judicious allocation of limited resources like BCG.

What is the regulatory status of Vesta Bladder Risk Stratify Dx?

Vesta Bladder Risk Stratify Dx has received FDA Breakthrough Device Designation, which expedites its development and review process. It is notable as the first AI-powered digital pathology prognostic test in bladder cancer to achieve this status, and the tests are processed in Valar Labs' CLIA-certified, CAP-accredited laboratory.

What are the current alternatives to Vesta Bladder Risk Stratify Dx for bladder cancer risk stratification?

Currently, clinicians primarily rely on traditional clinical and pathologic features such as tumor grade, stage, and size to estimate bladder cancer risk. While these tools are valuable, they are often imperfect and can leave significant uncertainty in treatment planning, which Vesta aims to address.

What is the cost of Vesta Bladder Risk Stratify Dx, and how is patient access supported?

While specific pricing for Vesta Bladder Risk Stratify Dx is not publicly detailed, Valar Labs states a commitment to patient access regardless of financial situation. They offer a Financial Access Program to support patients with financial needs.

What are the known limitations or scenarios where Vesta Bladder Risk Stratify Dx might not be as effective?

While Vesta provides improved resolution, traditional prognostic tools remain valuable, and the test is designed to complement them. The current information emphasizes its utility in addressing the 'gray zone' where existing guideline-based risk stratification can be conflicting or insufficient, particularly in heterogeneous non-muscle-invasive bladder cancer.